Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1508977

Transcriptome signature in the blood of neuromyelitis optica spectrum disorder under steroid tapering

Provisionally accepted
Ryohei Yamamura Ryohei Yamamura 1Makoto Kinoshita Makoto Kinoshita 1*Yoshiaki Yasumizu Yoshiaki Yasumizu 1,2,3Tomohiro Yata Tomohiro Yata 1Keigo Kihara Keigo Kihara 1Daisuke Motooka Daisuke Motooka 3,4Naoyuki Shiraishi Naoyuki Shiraishi 1Yasuko Sugiyama Yasuko Sugiyama 1Shohei Beppu Shohei Beppu 1Hisashi Murata Hisashi Murata 1Naoshi Koizumi Naoshi Koizumi 1Itsuki Sano Itsuki Sano 1Toru Koda Toru Koda 1Tatsusada Okuno Tatsusada Okuno 1*Hideki Mochizuki Hideki Mochizuki 1
  • 1 Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Ōsaka, Japan
  • 2 Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan
  • 3 Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan
  • 4 Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

The final, formatted version of the article will be published soon.

    Background: The advent of biologics has significantly transformed treatment strategies for neuromyelitis optica spectrum disorder (NMOSD). However, there are no biomarkers that predict relapses associated with steroid tapering; therefore, it is critical to identify potential indicators of disease activity. In this study, we collected peripheral blood mononuclear cells (PBMCs) from NMOSD patients during steroid tapering and performed bulk RNA sequencing to analyze changes in immune dynamics caused by steroid reduction. Methods: PBMCs were collected at 3–5 timepoints from 10 NMOSD patients at our hospital (including one relapse case), and bulk RNA sequencing was performed. All patients were positive for anti-AQP4 antibodies and had no history of biologic use.Results: In one relapsed patient, gene groups with decreased expression at relapse were observed predominantly in monocytes, with upregulation in anti-inflammatory pathways such as IL-10, while the upregulated genes were related to interferon signaling. Moreover, after steroid tapering, in non-relapsed patients, genes with increased expression were enriched in inflammatory pathways, represented by interferon signaling, while genes with decreased expression were enriched in pathways related to IL-10 and glucocorticoid receptors. Weighted gene co-expression network analysis identified modules that correlated with steroid dosage, and the modules inversely correlated with steroid dosage were enriched in monocytes, with marked immune signature of interferon pathway.Conclusion: This study identified peripheral blood transcriptome signatures that could lead to the identification of clinically relevant NMOSD disease activity biomarkers, and further highlights the pivotal role of interferon and IL-10 signaling in NMOSD.

    Keywords: NMOSD, steroid, Transcriptome signature, IL-10, interferon

    Received: 10 Oct 2024; Accepted: 16 Jan 2025.

    Copyright: © 2025 Yamamura, Kinoshita, Yasumizu, Yata, Kihara, Motooka, Shiraishi, Sugiyama, Beppu, Murata, Koizumi, Sano, Koda, Okuno and Mochizuki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Makoto Kinoshita, Department of Neurology, Graduate School of Medicine, Osaka University, Suita, 565-0871, Ōsaka, Japan
    Tatsusada Okuno, Department of Neurology, Graduate School of Medicine, Osaka University, Suita, 565-0871, Ōsaka, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.